Novasep plans to build a fully integrated antibody drug conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services.

The facility is planned to be commissioned in the second quarter of 2016. It will provide contract manufacturing in batch sizes from a few milligrams to 600 g to ADC drug developers during clinical trial and commercial development phases.

The expansion is part of Novasep's EUR 10 million investment in clinical and commercial scale ADC conjugation.

Source: Novasep